Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1677-1685

  Locke, Frederick L ^a   Zha, Yuan Yuan ^a   Zheng, Yan ^a   Driessens, Gregory ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; INTERLEUKIN 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL SURVIVAL; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION PROFILING; GENE INDUCTION; IMMUNIZATION; IMMUNOPOTENTIATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; THYMUS; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD28; CELL DIVISION; CELLS, CULTURED; CLONAL ANERGY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC;

EID: 84881422322     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202018     Document Type: Article

References (45)

1. Simpson, L., and R. Parsons. 2001. PTEN: life as a tumor suppressor. Exp. Cell Res. 264: 29-41.
2. Palomero, T., M. L. Sulis, M. Cortina, P. J. Real, K. Barnes, M. Ciofani, E. Caparros, J. Buteau, K. Brown, S. L. Perkins, et al. 2007. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13: 1203-1210.
3. Salmena, L., A. Carracedo, and P. P. Pandolfi. 2008. Tenets of PTEN tumor suppression. Cell 133: 403-414.
4. Schmidt-Weber, C. B., J. G. Wohlfahrt, C. A. Akdis, and K. Blaser. 2002. The phosphatidylinositol phosphatase PTEN is under control of costimulation and regulates proliferation in human T cells. Eur. J. Immunol. 32: 1196-1204.
5. Kane, L. P., P. G. Andres, K. C. Howland, A. K. Abbas, and A. Weiss. 2001. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFNgamma but not TH2 cytokines. Nat. Immunol. 2: 37-44.
6. Burr, J. S., N. D. Savage, G. E. Messah, S. L. Kimzey, A. S. Shaw, R. H. Arch, and J. M. Green. 2001. Cutting edge: distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-XL. J. Immunol. 166: 5331-5335.
7. Xue, L., L. Chiang, C. Kang, and A. Winoto. 2008. The role of the PI3K-AKT kinase pathway in T-cell development beyond the beta checkpoint. Eur. J. Immunol. 38: 3200-3207.
8. Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J. A. Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
9. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
10. Suzuki, A., M. T. Yamaguchi, T. Ohteki, T. Sasaki, T. Kaisho, Y. Kimura R. Yoshida, A. Wakeham, T. Higuchi, M. Fukumoto, et al. 2001. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14: 523-534.
11. Hagenbeek, T. J., and H. Spits. 2008. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 22: 608-619.
12. Zha, Y., R. Shah, F. Locke, A. Wong, and T. F. Gajewski. 2008. Use of Creadenovirus and CAR transgenic mice for efficient deletion of genes in postthymic T cells. J. Immunol. Methods 331: 94-102.
13. Wan, Y. Y., R. P. Leon, R. Marks, C. M. Cham, J. Schaack, T. F. Gajewski, and J. DeGregori. 2000. Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc. Natl. Acad. Sci. USA 97: 13784-13789.
14. Gajewski, T. F., J. Joyce, and F. W. Fitch. 1989. Antiproliferative effect of IFNgamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFNgamma. J. Immunol. 143: 15-22.
15. Tan, J. T., E. Dudl, E. LeRoy, R. Murray, J. Sprent, K. I. Weinberg, and C. D. Surh. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA 98: 8732-8737.
16. Driessens, G., Y. Zheng, F. Locke, J. L. Cannon, F. Gounari, and T. F. Gajewski. 2011. Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation. J. Immunol. 186: 784-790.
17. Rivas, F. V., J. P. O'Keefe, M. L. Alegre, and T. F. Gajewski. 2004. Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol. Cell. Biol. 24: 1628-1639.
18. Gajewski, T. F., D. Qian, P. Fields, and F. W. Fitch. 1994. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc. Natl. Acad. Sci. USA 91: 38-42.
19. Gajewski, T. F., J. C. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154: 5637-5648.
20. Kacha, A. K., F. Fallarino, M. A. Markiewicz, and T. F. Gajewski. 2000. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6- deficient mice. J. Immunol. 165: 6024-6028.
21. Li, C., and W. H. Wong. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA 98: 31-36.
22. Edgar, R., M. Domrachev, and A. E. Lash. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30: 207-210.
23. Marks, R. E., A. W. Ho, F. Rivas, E. Marshall, S. Janardhan, and T. F. Gajewski. 2003. Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem. Biophys. Res. Commun. 312: 691-696.
24. Fields, P. E., T. F. Gajewski, and F. W. Fitch. 1996. Blocked Ras activation in anergic CD4+ T cells. Science 271: 1276-1278.
25. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
26. Pagès, F., M. Ragueneau, R. Rottapel, A. Truneh, J. Nunes, J. Imbert, and D. Olive. 1994. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369: 327-329.
27. Williams, M. E., C. M. Shea, A. H. Lichtman, and A. K. Abbas. 1992. Antigen receptor-mediated anergy in resting T lymphocytes and T cell clones. Correlation with lymphokine secretion patterns. J. Immunol. 149: 1921-1926.
28. Liu, Y., and C. A. Janeway, Jr. 1991. Monoclonal antibodies against T cell receptor/CD3 complex induce cell death of Th1 clones in the absence of accessory cells. Adv. Exp. Med. Biol. 292: 105-113.
29. Andris, F., S. Denanglaire, F. de Mattia, J. Urbain, and O. Leo. 2004. Naive T cells are resistant to anergy induction by anti-CD3 antibodies. J. Immunol. 173: 3201-3208.
30. Zheng, Y., G. M. Delgoffe, C. F. Meyer, W. Chan, and J. D. Powell. 2009. Anergic T cells are metabolically anergic. J. Immunol. 183: 6095-6101.
31. Buckler, J. L., P. T. Walsh, P. M. Porrett, Y. Choi, and L. A. Turka. 2006. Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J. Immunol. 177: 4262-4266.
32. Chemnitz, J. M., R. V. Parry, K. E. Nichols, C. H. June, and J. L. Riley. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173: 945-954.
33. Lee, K. M., E. Chuang, M. Griffin, R. Khattri, D. K. Hong, W. Zhang, D. Straus, L. E. Samelson, C. B. Thompson, and J. A. Bluestone. 1998. Molecular basis of T cell inactivation by CTLA-4. Science 282: 2263-2266.
34. Nguyen, T. V., Y. Ke, E. E. Zhang, and G. S. Feng. 2006. Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J. Immunol. 177: 5990-5996.
35. Tripathi, P., R. Madan, C. Chougnet, S. Divanovic, X. Ma, L. M. Wahl, T. Gajewski, C. L. Karp, and D. A. Hildeman. 2006. An adenoviral vector for probing promoter activity in primary immune cells. J. Immunol. Methods 311: 19-30.
36. Zheng, Y., Y. Zha, G. Driessens, F. Locke, and T. F. Gajewski. 2012. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J. Exp. Med. 209: 2157-2163.
37. Stiles, B., Y. Wang, A. Stahl, S. Bassilian, W. P. Lee, Y. J. Kim, R. Sherwin, S. Devaskar, R. Lesche, M. A. Magnuson, and H. Wu. 2004. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. [corrected] Proc. Natl. Acad. Sci. USA 101: 2082-2087.
38. Wijesekara, N., D. Konrad, M. Eweida, C. Jefferies, N. Liadis, A. Giacca, M. Crackower, A. Suzuki, T. W. Mak, C. R. Kahn, et al. 2005. Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol. Cell. Biol. 25: 1135-1145.
39. Okkenhaug, K., L. Wu, K. M. Garza, J. La Rose, W. Khoo, B. Odermatt, T. W. Mak, P. S. Ohashi, and R. Rottapel. 2001. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat. Immunol. 2: 325-332.
40. Janardhan, S. V., K. Praveen, R. Marks, and T. F. Gajewski. 2011. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS ONE 6: e24931.
41. Zheng, Y., Y. Zha, R. M. Spaapen, R. Mathew, K. Barr, A. Bendelac, and T. F. Gajewski. 2013. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol. Immunol. 55: 283-291.
42. Nakashima, N., P. M. Sharma, T. Imamura, R. Bookstein, and J. M. Olefsky. 2000. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3- L1 adipocytes. J. Biol. Chem. 275: 12889-12895.
43. Kotelevets, L., J. van Hengel, E. Bruyneel, M. Mareel, F. van Roy, and E. Chastre. 2001. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J. Cell Biol. 155: 1129-1135.
44. Subramanian, K. K., Y. Jia, D. Zhu, B. T. Simms, H. Jo, H. Hattori, J. You, J. P. Mizgerd, and H. R. Luo. 2007. Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 109: 4028-4037.
45. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.